ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Halted

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Mar 22, 2021 2:51pm

138 Views

Post# 32851567

RE:RE:RE:RE:RE:Halted

i don't think PMN310 is going to stay in the back burner for long. We can be as sarcastic as We like but no where yo go but up from here . Change and the fact someone is willing to put $$ on pmn it's good news

M101 wrote: Got to expand managment, absolutely. Maybe get rid of the lab to help pay for it, that guy Cashman wtf does he do anyway. Golden parachute for Elliot too, $10,000,000 would buy a nice thank-you card.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario